1 |
Surratt HL, Yeager HJ, Adu A, González EA, Nelson EO, Walker T. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives. Front Psychiatry 2022;13:905314. [DOI: 10.3389/fpsyt.2022.905314] [Reference Citation Analysis]
|
2 |
Barré T, Mercié P, Lions C, Miailhes P, Zucman D, Aumaître H, Esterle L, Sogni P, Carrieri P, Salmon-Céron D, Marcellin F; ANRS CO13 HEPAVIH Study Group. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data). AIDS Res Ther 2022;19:15. [PMID: 35292069 DOI: 10.1186/s12981-022-00440-9] [Reference Citation Analysis]
|
3 |
Barré T, Mercié P, Marcellin F, Esterle L, Duvivier C, Teicher E, Bureau M, Chas J, Salmon-Céron D, Sogni P, Carrieri MP, Wittkop L, Protopopescu C; ANRS CO13 HEPAVIH Study Group. HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). AIDS Behav 2021;25:4141-53. [PMID: 33903998 DOI: 10.1007/s10461-021-03277-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
4 |
Khalsa JH, Mathur P. Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses 2021;13:1363. [PMID: 34372569 DOI: 10.3390/v13071363] [Reference Citation Analysis]
|